Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Stem Cell Transplantation: early-phase trial registry

A small indexed set (9 trials) with no open enrollment listed right now.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · none currently recruiting · #1,916 of 28,707 conditions by registered trial count

Stem Cell Transplantation: 9 US clinical trials tracked, none currently recruiting.

Stem Cell Transplantation is the subject of 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 2 of these trials.

Enrollment posture brief

Registry condition stem-cell-transplantation

OPEN 0 | RECR 0% | LATE 0 | EARLY 4 | RANK #1916 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%Stem Cell Transplantatio (th…0%
Open-enrollment share among volume-matched conditions near Stem Cell Transplantation

Stem Cell Transplantation has no open enrollment in this registry pull (9 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stem Cell Transplantation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stem Cell Transplantation is recruiting below its size-band peers.

    0 of 9 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stem Cell Transplantation research.

    National Heart, Lung, and Blood Institute (NHLBI) accounts for 2 of 9 trials (22.2%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Stem Cell Transplantation trials plan to enrol fewer than 100 people.

    Median target enrolment is 31 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.

  4. Stem Cell Transplantation splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING NA 60 participants

Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation

University of Miami

NCT05968963

ACTIVE NOT RECRUITING Phase 2 56 participants

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

National Heart, Lung, and Blood Institute (NHLBI)

NCT02105766

ACTIVE NOT RECRUITING NA 17 participants

Feasibility Neurocognitive Outcome After Transplant

Stanford University

NCT02300961

COMPLETED 70 participants

C-Reactive Protein as a Predictor of Stem Cell Transplant Complications

Ann & Robert H Lurie Children's Hospital of Chicago

NCT00179868

COMPLETED Phase 2 60 participants

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

M.D. Anderson Cancer Center

NCT00857389

COMPLETED Phase 1 31 participants

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

University of Miami

NCT01087996

COMPLETED Early Phase 1 26 participants

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

Yale University

NCT00612274

COMPLETED 24 participants

Investigating Cytokine Genes of Stem Cell Donors

National Heart, Lung, and Blood Institute (NHLBI)

NCT00353821

COMPLETED 15 participants

Post-HSCT Medication Adherence mHealth App

Micah Skeens

NCT04976933

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Named interventions

Most-linked intervention names on Stem Cell Transplantation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sirolimus Drug
2 trials
Allo-hMSCs Biological
1 trials
Auto-hMSCs Biological
1 trials
Thymoglobulin (ATG) Drug
1 trials
mHealth adherence app Behavioral
1 trials
C-Reactive Protein levels Behavioral
1 trials
Cognitive rehabilitation program Behavioral
1 trials
Radiotherapy Procedure
1 trials

US sites by state

Facility locations filed on Stem Cell Transplantation trials. A trial with sites in several states counts in each.

Maryland 3 trials
Florida 2 trials
Texas 1 trials
Ohio 1 trials
Illinois 1 trials
Connecticut 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stem Cell Transplantation page

9 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stem Cell Transplantation condition card totals 9 registered trials; most-linked intervention Sirolimus; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.